2022年6月5日

分享我的智能機器(MIMs)——一個利用係統生物學、生物信息學和人工智能力量的領導者，推出了一款產品，準備改變公司為腫瘤學臨床試驗做準備的方式。使用專門為他們構建的複雜的係統生物學和機器學習平台，生命科學家現在能夠預測對新療法的良好反應，其性能比其他現有方法高出兩倍以上。此外，他們能夠在一天內完成一個月的工作，以生物信息學和數據科學谘詢服務十分之一的成本提供結果。MIMs在腫瘤學領域的軟件解決方案使用了來自200多種癌症類型的16,000名患者的表達數據，能夠為個別患者的藥物作用機製和藥物協同作用提供關鍵見解。“作為一名生物學家，我一直夢想在涉及下一代測序的研究中更加自主;能夠探索自己的想法和見解，而不需要成本、時間，也不依賴他人來幫助我處理和分析自己的數據，”MIMs的聯合創始人兼首席執行官莎拉·詹娜說。“有了MIMs，生命科學家現在可以獨立利用係統生物學、人工智能的力量，以及他們自己在癌症生物學方麵的深厚人類知識和經驗，推動創新和藥物發現的邊界。”MIMs的腫瘤研究產品提供科學的見解，以支持臨床前階段適應症優先級的戰略決策。它使研究人員能夠提高II期和III期臨床試驗的成功率;探索新的有效聯合療法; and accelerate early high-value biomarkers to accelerate companion test development. Related Posts MIMs’ platform integrates the company’s MIMsight Knowledge Base—which combines billions of data points and other information extracted from scientific literature, public databases, multi-omic and clinical patient data—and MIMs’ proprietary GI2 algorithm, which infers genetic interactions within patient tumors and immune systems. The platform creates vivid human cartographies of individual patients, which deliver previously unimagined levels of precise insight used to classify patients into subgroups, identify their molecular and clinical characteristics, predict their response to new therapies, and identify powerful therapeutic targets and biomarkers. Jenna continues, laughing. “Six years ago, when we explained to people what we were building our platform to do, they called it science fiction! Today, these same people are buying annual licenses.” My Intelligent Machines will be in Chicago this week, at the American Society of Clinical Oncology (ASCO) Meeting and invites people to stop by Booth IH20 to learn more about this exciting new approach. To celebrate the product launch, and being back at ASCO in-person, MIMs is offering special promotional pricing, with a 30-percent discount on its Lite and Plus SaaS platform packages. The company also encourages those interested in a free 30-day trial to contact them directly.